Your browser is no longer supported. Please, upgrade your browser.
VCEL Vericel Corporation monthly Stock Chart
VCEL [NASD]
Vericel Corporation
Index- P/E24960.00 EPS (ttm)0.00 Insider Own1.09% Shs Outstand45.27M Perf Week1.71%
Market Cap1.13B Forward P/E95.27 EPS next Y0.26 Insider Trans-6.86% Shs Float44.94M Perf Month22.77%
Income0.10M PEG- EPS next Q0.21 Inst Own96.50% Short Float9.36% Perf Quarter50.27%
Sales118.30M P/S9.57 EPS this Y-8.20% Inst Trans-2.01% Short Ratio8.10 Perf Half Y73.57%
Book/sh2.53 P/B9.87 EPS next Y1771.43% ROA0.10% Target Price29.25 Perf Year35.28%
Cash/sh1.89 P/C13.24 EPS next 5Y- ROE0.10% 52W Range6.78 - 26.22 Perf YTD43.45%
Dividend- P/FCF150.92 EPS past 5Y37.10% ROI-10.10% 52W High-4.81% Beta3.01
Dividend %- Quick Ratio5.40 Sales past 5Y32.60% Gross Margin67.10% 52W Low268.14% ATR1.17
Employees241 Current Ratio5.90 Sales Q/Q5.90% Oper. Margin-0.50% RSI (14)64.10 Volatility4.72% 5.14%
OptionableYes Debt/Eq0.00 EPS Q/Q2.80% Profit Margin0.10% Rel Volume1.38 Prev Close23.17
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout0.00% Avg Volume519.75K Price24.96
Recom1.60 SMA209.31% SMA5018.56% SMA20055.31% Volume715,456 Change7.73%
Sep-17-20Initiated Truist Buy $24
Oct-09-19Initiated H.C. Wainwright Buy $19
Feb-28-19Downgrade Needham Buy → Hold
Aug-08-18Reiterated Needham Buy $15 → $14
Jul-16-18Upgrade Ladenburg Thalmann Neutral → Buy
Apr-04-18Initiated Leerink Partners Outperform $15
Mar-06-18Reiterated Needham Buy $5 → $15
Mar-06-18Downgrade Ladenburg Thalmann Buy → Neutral
Mar-05-18Reiterated BTIG Research Buy $8 → $13
Jun-21-17Initiated BTIG Research Buy $6
Mar-13-17Reiterated Needham Buy $9 → $6
Dec-22-16Initiated Piper Jaffray Overweight $6
Nov-09-16Reiterated Needham Buy $12 → $9
Apr-05-16Downgrade BofA/Merrill Buy → Neutral
Mar-11-16Upgrade Needham Hold → Buy $12
Nov-09-20 11:44AM  
Nov-05-20 10:32PM  
08:00AM  
Nov-03-20 09:43AM  
05:54AM  
Nov-02-20 08:30AM  
06:40AM  
Oct-30-20 03:54PM  
Oct-29-20 11:30AM  
11:24AM  
Oct-22-20 08:30AM  
Oct-14-20 08:00AM  
Oct-12-20 10:35AM  
Oct-09-20 08:30AM  
Sep-16-20 07:30AM  
07:30AM  
Sep-09-20 08:30AM  
Sep-04-20 08:30AM  
Aug-25-20 08:25AM  
07:00AM  
Aug-10-20 09:19AM  
Aug-05-20 08:00AM  
Jul-22-20 08:30AM  
Jul-15-20 08:33AM  
Jul-09-20 08:30AM  
Jun-30-20 07:00AM  
07:00AM  
Jun-23-20 01:48PM  
May-28-20 03:38AM  
May-27-20 11:14AM  
May-26-20 09:27AM  
May-13-20 08:30AM  
May-06-20 12:02AM  
May-05-20 09:34AM  
08:00AM  
Apr-22-20 08:30AM  
Apr-10-20 09:00AM  
Apr-08-20 08:30AM  
Apr-02-20 02:58PM  
09:00AM  
Mar-31-20 09:39AM  
Mar-10-20 03:17AM  
Mar-04-20 08:29AM  
Mar-03-20 09:28AM  
Feb-25-20 08:00AM  
06:15AM  
Feb-24-20 10:04AM  
09:05AM  
09:02AM  
Feb-19-20 08:00AM  
Feb-14-20 09:49AM  
Feb-13-20 08:48AM  
08:44AM  
Feb-12-20 08:06AM  
07:38AM  
Feb-11-20 08:00AM  
Feb-10-20 10:20AM  
Jan-31-20 12:46PM  
Jan-09-20 08:00AM  
Jan-06-20 06:30AM  
Dec-19-19 07:07AM  
Dec-17-19 02:46PM  
Dec-11-19 09:48AM  
Dec-06-19 07:20AM  
Nov-06-19 10:55AM  
09:00AM  
Nov-05-19 08:00AM  
Oct-31-19 03:43PM  
Oct-28-19 08:18PM  
Oct-22-19 08:30AM  
Oct-09-19 03:09PM  
Oct-02-19 07:30AM  
Sep-27-19 08:00AM  
Sep-23-19 02:19PM  
Sep-18-19 08:00AM  
Sep-04-19 08:00AM  
Aug-08-19 06:28PM  
Aug-06-19 12:23PM  
08:20AM  
07:00AM  
Aug-01-19 08:00AM  
Jul-23-19 08:00AM  
Jul-09-19 10:43PM  
Jun-29-19 08:15AM  
08:12AM  
Jun-18-19 10:30AM  
May-29-19 07:30AM  
May-15-19 08:00AM  
May-14-19 05:40PM  
May-09-19 11:30AM  
May-08-19 06:24AM  
May-07-19 08:53PM  
07:00AM  
02:00AM  
02:00AM  
May-06-19 07:45AM  
May-05-19 05:49PM  
Apr-30-19 10:32AM  
Apr-25-19 08:30AM  
Apr-03-19 08:30AM  
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to dilated cardiomyopathy. In addition, its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ZERBE ROBERT L MDDirectorNov 23Option Exercise3.2530,00097,50049,295Nov 24 04:09 PM
ZERBE ROBERT L MDDirectorNov 23Sale23.5517,500412,12531,795Nov 24 04:09 PM
Halpin MichaelChief Operating OfficerJun 23Option Exercise7.2014,751106,20716,373Jun 24 04:19 PM
Halpin MichaelChief Operating OfficerJun 23Sale15.0114,751221,4131,622Jun 24 04:19 PM
Halpin MichaelChief Operating OfficerJun 16Option Exercise2.652,8907,6595,624Jun 18 04:03 PM
Halpin MichaelChief Operating OfficerJun 16Sale15.004,00260,0301,622Jun 18 04:03 PM
Colangelo DominickPresident and CEOMay 08Option Exercise2.7513,12536,094210,492May 08 04:09 PM
ZERBE ROBERT L MDDirectorApr 29Option Exercise0.001,750019,295May 01 04:17 PM
GILMAN STEVEN CDirectorApr 29Option Exercise0.001,75001,750May 01 04:15 PM
Hagen HeidiDirectorApr 29Option Exercise0.001,75001,750May 01 04:14 PM
MCLAUGHLIN KEVIN FDirectorApr 29Option Exercise0.001,75001,750May 01 04:13 PM
Wotton Paul KDirectorApr 29Option Exercise0.001,75001,750May 01 04:12 PM
Rubino Alan LDirectorApr 29Option Exercise0.001,75002,644May 01 04:09 PM
MICHEL GERARD JCFO and VP, Corp. DevelopmentApr 01Option Exercise2.9891,157271,482253,865Apr 03 04:02 PM
Colangelo DominickPresident and CEOFeb 13Option Exercise2.4023,43856,204196,229Feb 18 04:26 PM
Halpin MichaelChief Operating OfficerFeb 06Option Exercise0.001,87503,164Feb 10 05:04 PM
Colangelo DominickPresident and CEOFeb 06Option Exercise0.006,9370175,970Feb 10 05:03 PM
MICHEL GERARD JCFO and VP, Corp. DevelopmentFeb 06Option Exercise0.003,0000162,732Feb 10 05:02 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.